1. Home
  2. DRCT vs NEUP Comparison

DRCT vs NEUP Comparison

Compare DRCT & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Direct Digital Holdings Inc.

DRCT

Direct Digital Holdings Inc.

HOLD

Current Price

$0.10

Market Cap

8.9M

Sector

Technology

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.24

Market Cap

10.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
DRCT
NEUP
Founded
2018
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
8.9M
10.3M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
DRCT
NEUP
Price
$0.10
$4.24
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$6.00
$28.00
AVG Volume (30 Days)
27.8M
151.5K
Earning Date
11-06-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$35,369,000.00
$15,649,448.00
Revenue This Year
N/A
N/A
Revenue Next Year
$25.40
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.09
$2.90
52 Week High
$6.59
$21.40

Technical Indicators

Market Signals
Indicator
DRCT
NEUP
Relative Strength Index (RSI) 24.96 35.98
Support Level $0.09 $4.10
Resistance Level $0.18 $4.60
Average True Range (ATR) 0.03 0.30
MACD -0.00 0.25
Stochastic Oscillator 8.15 12.22

Price Performance

Historical Comparison
DRCT
NEUP

About DRCT Direct Digital Holdings Inc.

Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: